AGM/EGMMay 22, 2026, 04:53 PM
Mineralys Therapeutics Stockholders Elect Directors, Ratify Auditor
AI Summary
Mineralys Therapeutics, Inc. held its 2026 annual meeting of stockholders on May 21, 2026. Stockholders approved the election of three Class III directors: Srinivas Akkaraju, Brian Taylor Slingsby, and Daphne Karydas, each for a three-year term. Additionally, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
Key Highlights
- Srinivas Akkaraju elected as Class III director with 40,667,555 votes For.
- Brian Taylor Slingsby elected as Class III director with 42,487,140 votes For.
- Daphne Karydas elected as Class III director with 66,626,766 votes For.
- Appointment of Ernst & Young LLP as auditor ratified with 72,648,272 votes For.
Price Impact
More from MLYS